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Abstract 
The Antarctic region is of particular interest to natural products chemists because it 
remains relatively unexplored and possesses a wealth of unique biodiversity. Organisms that 
thrive in this region must produce different chemical defenses to survive in the harsh polar 
environment, making their secondary metabolites original and potentially useful as drugs for 
human disease. These compounds often have very complex structures, making their syntheses 
difficult and impractical. With this knowledge, five Antarctic marine invertebrates were 
extracted in search of their secondary metabolites. The chemical isolation studies were 
performed by macroorganism solvent extraction followed by chromatographic separation and 
purification of metabolites guided by proton nuclear magnetic resonance spectroscopy. The 
isolates were screened in malaria, leishmaniasis, and cytotoxicity bioassays. Based on the 
bioassay data, an extract of interest was chromatographed by high performance liquid 
chromatography and analyzed by liquid chromatography-mass spectrometry. Potential pure 
compounds could not be further isolated or characterized due to an insufficient quantity. 
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Introduction 
 
 Pharmacognosy is a field of science devoted to the search for new drugs from natural 
sources, along with the study of the physical, chemical, biochemical, and biological properties of 
drugs, as defined by the American Society of Pharmacognosy.1 Humans have been combating 
disease for thousands of years. Before the days of pharmaceutical development, societies cured 
diseases using the elements of their natural environments. Knowledge of which plants healed 
specific ailments was accumulated over years by a mixture of trial and error and mere chance. 
Therefore, it is not surprising that many of the pharmaceutical drugs on the market today are 
derived from natural products, or chemicals that are produced by living organisms, including 
plants, animals, fungi, and bacteria. Many of these chemicals exhibit biological activity that 
makes them ideal candidates for drug discovery and development. In fact, over 60% of cancer 
drugs and 75% of infectious disease drugs are developed from natural products.2 The percentage 
is even greater for specific indications. For example, 78% of antibacterial and 74% of anticancer 
compounds originate from natural products.3 Some that are currently in medicinal use include 
penicillins (antibiotics), morphine (an analgesic), and paclitaxel (the anticancer drug taxol).4 
   
Figure 1 Left to right: penicillin core structure, morphine, paclitaxel. 
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With the advent of new technologies, the focus in drug discovery has shifted toward 
combinatorial chemistry and virtual screening of drug-target interactions.3, 5 However, the 
available drug libraries are limited to known compounds and by the human imagination. There is 
also much greater diversity among natural products than combinatorial molecules. As a result, 
compounds in combinatorial libraries occupy a smaller volume of chemical space, the space 
spanned by all combinations of nuclei in all topology isomers, than either natural products or 
drugs.3, 6  
  
 
Figure 2 Plots representing the volume of chemical space occupied by a) combinatorial compounds, b) natural 
products, and c) drugs6. Combinatorial molecules occupy a defined region of this space, while natural products and 
drugs occupy this same space as well as a larger volume. There is obvious overlap between the diversity of natural 
products and drugs.  
 
In traditional natural products isolation, the resulting isolate often has a complex structure 
that would be difficult and impractical to synthesize. Characterization of these molecules aids in 
the discovery of therapeutic mechanisms of action and biosynthetic pathways and also provides a 
6 
 
foundation for developing natural product analogs.7 Medicinal chemistry is generally governed 
by Lipinski’s Rule of Five, which is used to identify small molecules that are likely to possess 
desirable pharmacokinetic properties. The criteria for these molecules are that they have no more 
than five hydrogen bond donors, no more than ten hydrogen bond acceptors, a molecular weight 
less than 500 daltons, and a log P less than five. However, many important natural products 
violate this rule, as their molecular weights often exceed 500 daltons.7 One such molecule is 
palmerolide A, which is a macrocyclic polyketide isolated from the Antarctic tunicate Synoicum 
adareanum that exhibits activity against melanoma by inhibiting vacuolar ATPase.8 Another 
similar class of polyketides is the chrondropsins, which have been isolated from a number of 
marine sponges including Ircinia ramosa9 and Chondropsis sp.10 Like palmerolide A, these 
molecules inhibit vacuolar ATPases.11 
 
 
Figure 3 The top is palmerolide A and the bottom is the chondropsin backbone. 
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 The ocean comprises approximately seventy percent of the earth’s surface. 
Consequentially, the number of marine organisms greatly exceeds the number of terrestrial 
organisms. The biodiversity of the marine environment is so great that it has become one of the 
focuses of a number of scientific disciplines over the past few decades. The majority of the 
ocean’s organisms thrive on the interface between land and sea, which constitutes less than one 
percent of the earth’s surface.12 As a result, there is great competition among these species for 
food and space, especially in the case of sessile organisms such as coral, sponges, and tunicates.  
In response to this, many species have developed chemical mechanisms to defend 
themselves.12 These chemical defenses are secondary metabolites, which are often terpenoids, 
alkaloids, polyketides, peptides, sugars, and steroids.12 In many cases, these molecules exhibit 
activity against an array of human diseases. In the past, secondary metabolites were thought to be 
waste products and were disregarded, but their importance in drug discovery has recently been 
recognized.13 So far, there have been more than 16,000 natural products isolated from marine 
organisms,14 which have proven to yield large quantities of chemically diverse and biologically 
active molecules.15 For instance, prostaglandins, which are used as non-steroidal anti-
inflammatory drugs (NSAIDs), were first reported in high yields from Plexaura homomalla, a 
Caribbean gorgonean.14 Another important class of compounds is the statins, which have been 
isolated from a number of fungi.4, 15 
   
Figure 4 On the left is prostaglandin E1 (PGE1); on the right is lovostatin 
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The Polar Regions have surprisingly great biodiversity unique to their climate, but these 
habitats are among the least explored due to their lack of accessibility. As a result, the 
ecosystems have remained relatively undisturbed and uninfluenced by humans. In addition, the 
Antarctic has been isolated for 25 million years by the Circumantarctic Current.16 Organisms that 
thrive in these harsh, cold environments are of interest because their chemical ecology may differ 
significantly from organisms in warmer climates. Therefore, their secondary metabolites are 
particularly appealing because they are exclusive to species of the Polar Regions. The benthos of 
Antarctica is unique in that up to 55% of the ocean floor is covered in a variety of sponges16, 
which are often the dominant organisms as a result.17 Five sessile Antarctic marine invertebrates 
were investigated in an attempt to identify novel secondary metabolites. Separations were 
performed using a variety of chromatography techniques in conjunction with proton nuclear 
magnetic resonance spectroscopy and bioassays to guide the isolation. Additional studies remain 
in order to obtain enough isolate for thorough purification and structure elucidation.  
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Experimental Methods 
 
Five Antarctic marine invertebrates were extracted for analysis. An orange-top sponge 
with yellow interior (PSC01-53, 240 g freeze-dried), a calcaneus bryozoan (PSC03-133, 300 g 
freeze-dried), and a dock finger sponge (PSC08-01, 1.42 kg freeze-dried) were collected by 
SCUBA by the Baker research group from the waters surrounding Palmer Station, Antarctica in 
2001, 2003, and 2008, respectively. Isodictya setifera (LMGSC10-108, 120 g freeze-dried) and 
Didemnum sp. (LMGSC10-96, 120 g freeze-dried) were collected by trawling by the Baker 
research group from Low Island, Antarctica in 2010. The five lyophilized samples were 
exhaustively extracted in 1:1 CH3OH and CH2Cl2. The organisms were then allowed to dry for 
twenty-four hours before being similarly extracted in 1:1 CH3OH and H2O (Appendix A). Proton 
nuclear magnetic resonance (1H NMR) spectra were obtained for each extract (Appendix B). 
The lipophilic extract (50% CH2Cl:CH3OH) of each organism was chromatographed by 
normal phase medium pressure liquid chromatography (MPLC) using a solvent gradient of 100% 
hexane to 100% EtOAc (Appendix C). All fractions collected were then dissolved in dimethyl 
sulfoxide (DMSO) at a concentration of 2 mg/mL. Aliquots of 200 µL of each fraction were 
transferred to a 96-well plate, which was submitted to Dr. Dennis Kyle for malaria testing with 
Plasmodium falciparum 3D7, cytotoxicity testing using the A549 cell line, and leishmaniasis 
testing against Leishmania donovani. 
Based on the results of the bioassay, the malaria hit (LMGSC10-108-6-7) was dissolved 
in 50% CH3CN:CH3OH in preparation for a reverse phase MPLC wet injection. However, the 
sample was not completely soluble, so it was chromatographed in two separate experiments 
using the dry, insoluble portion of the sample and the liquid extract. Both samples were 
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chromatographed with a 30-g Teledyne Isco RediSep Gold High Performance C18 column using 
a solvent gradient of 10% H2O:CH3CN to 100% CH3CN, followed by a 100% CH3OH wash at a 
flow rate of 35 mL/min (Appendix C). Both injections yielded five fractions each, which were 
analyzed by 1H NMR in deuterated methanol (CD3OD).  
Liquid chromatography-mass spectrometry (LC-MS) data was obtained for fraction 4 
(LMGSC10-108-6-7-4b) of the CH3CN:CH3OH extract to determine an appropriate solvent 
gradient and absorption wavelengths since the compound did not absorb at 254 nm. This fraction 
was then chromatographed by reverse phase high performance liquid chromatography on a 4.6 x 
250 mm Phenomenex Luna C18 5μ column using a solvent gradient of 10% H2O:CH3CN to 
100% CH3CN with 210- and 225-nm detection, yielding 13 fractions (Appendix C). 1H NMR 
spectra were obtained for each fraction in deuterated dimethyl sulfoxide (DMSO-d6).  
Fraction 11 (LMGSC10-108-6-7-4b-11, 0.8 mg) was dissolved in CH3OH and submitted 
for LC-MS to determine the purity of the sample, although the quantity of sample material was 
insufficient for additional purification (Appendix C). 
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Results and Discussion 
 
Five Antarctic marine invertebrates were extracted in organic solvents. The lipophilic 
extract (50% CH2Cl2:CH3OH) of each organism was chromatographed by normal phase MPLC 
and the resulting fractions were submitted for malaria, leishmaniasis, and cytotoxicity bioassays 
(Appendix D). Eleven fractions exhibited mild antimalarial activity with little cytotoxicity 
(secondary interests, partial hits) and one fraction, LMGSC10-108-6-7, exhibited moderate 
antimalarial activity with low cytotoxicity (primary interest, hit). None of the fractions submitted 
exhibited activity against leishmaniasis. Although the isolation could not be fully guided by 
bioassay in the interest of time, the fractions generated from the separation of the antimalarial hit 
will be submitted for bioassay.  
The antimalarial hit, LMGSC10-108-6-7, was further chromatographed by reverse phase 
MPLC. A fraction of interest, identified by its 1H NMR spectrum, was separated by reverse 
phase HPLC. A fraction of interest was again identified using 1H NMR, which revealed the 
presence of an aromatic ring. LC-MS data was obtained, indicating that the sample is a mixture 
of components; however, the mass of the sample is insufficient for further purification.  
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Appendix A: Fractionation Schemes  
 
Orange-top sponge, 
yellow interior
(PSC01-53)
240 g
50% CH3OH:CH2Cl2 (-6)
16.5 g
Fraction 1a*
18.6 mg
Fraction 1b
4.4 mg
Fraction 2a
153 mg
Fraction 2b*
642 mg
Fraction 3a
638 mg
Fraction 3b
109 mg
Fraction 4a
151 mg
Fraction 4b
243 mg
Fraction 5a*
71.6 mg
Fraction 5b
32.3 mg
Fraction 6a
24.2 mg
Fraction 6b*
9.6 mg
Fraction 7a
15.8 mg
Fraction 7b
19.2 mg
Fraction 8a
194 mg
Fraction 8b
252 mg
Fraction 9a
306 mg
Fraction 9b
2.11 g
Fraction 10a
1.23 g
Fraction 10b
947 mg
Fraction 11a
773 mg
Fraction 12a
676 mg
Fraction 13a
2.51 g
50% H2O:CH3OH (-7)
45.0 g 
* Indicates fractions that 
exhibited antimalarial activity 
Silica column (80 g) 
100% hexane to 100% EtOAc 
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calcaneus bryozoan
(PSC03-133)
300 g
50% CH3OH:CH2Cl2 (-6)
5.10 g
Fraction 1
20.2 mg
Fraction 2
26.7 mg
Fraction 3
304 mg
Fraction 4
22.6 mg
Fraction 5
49.9 mg
Fraction 6*
54.5 mg
Fraction 7*
40.7 mg
Fraction 8
22.9 mg
Fraction 9*
19.0 mg
Fraction 10*
6.1 mg
Fraction 11
4.3 mg
Fraction 12
4.7 mg
Fraction 13
9.2 mg
Fraction 14
1.5 mg
Fraction 15
1.5 mg
Fraction 16
0.4 mg
Fraction 17
13.8 mg
50% H2O:CH3OH (-7)
8.96 g
* Indicates fractions that 
exhibited antimalarial activity 
Silica column (80 g) 
100% hexane to 100% EtOAc 
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Didemnum sp.
(LMGSC10-96)
120 g
50% CH3OH:CH2Cl2 (-6)
12.0 g
Fraction 1
184 mg
Fraction 2
616 mg
Fraction 3*
177 mg
Fraction 4
78.3 mg
Fraction 5
42.1 mg
Fraction 6*
456 mg
Fraction 7
2.77 g
Fraction 8
3.33 g
Fraction 9
1.32 g
50% H2O:CH3OH (-7)
16.9 g
* Indicates fractions that 
exhibited antimalarial activity 
Silica column (120 g) 
100% hexane to 100% EtOAc 
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dock finger sponge
(PSC08-01)
1.42 kg
50% CH3OH:CH2Cl2 (-6)
74.3 g 
Vial B
7.53 g
Fraction 1
20.1 mg
Fraction 2
14.4 mg
Fraction 3
751 mg
Fraction 4
97.1 mg
Fraction 5
91.1 mg
Fraction 6
1.15 g
Fraction 7
1.55 g
Fraction 8
1.17 g
Fraction 9
188 mg
Fraction 10
243 mg
50% H2O:CH3OH (-7)
73.5 g 
Silica column (80 g) 
100% hexane to 100% EtOAc 
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Isodictya setifera
(LMGSC10-108)
120 g
50% CH3OH:CH2Cl2 (-6)
7.98 g
Fraction 1
9.2 mg
Fraction 2
127 mg
Fraction 3
174 mg
Fraction 4
132 mg
Fraction 5
52.5 mg
Fraction 6
49.2 mg
Fraction 7*
780 mg
Fraction 1a
0.7 mg
Fraction 1b
468 mg
Fraction 2a
27.0 mg
Fraction 2b
2.7 mg
Fraction 3a
6.3 mg
Fraction 3b
22.3 mg
Fraction 4a
5.3 mg
Fraction 4b
23.2 mg
Fraction 1
1.0 mg
Fraction 2
2.8 mg
Fraction 3
2.5 mg
Fraction 4
1.7 mg
Fraction 5
1.7 mg
Fraction 6
2.5 mg
Fraction 7
2.7 mg
Fraction 8
1.7 mg
Fraction 9
1.2 mg
Fraction 10
0.5 mg
Fraction 11
0.8 mg
Fraction 12
2.5 mg
Fraction 13
1.4 mg
Fraction 5a
1.6 mg
Fraction 5b
7.1 mg
Fraction 8
3.23 g
Fraction 9*
575 mg
Fraction 10
163 mg
Fraction 11
123 mg
50% H2O:CH3OH (-7)
12.4 g
* Indicates fractions that 
exhibited antimalarial activity 
Silica column (80 g) 
100% hexane to 100% EtOAc 
C18 column (30 g) 
100% H2O to 100% CH3OH 
C18 column (4.6x250 mm, 5μ) 
10% CH3CN:H2O to 100% CH3CN 
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Appendix B: 1H NMR Spectra 
 
 
1H NMR spectrum (400 MHz, CDCl3) of the lipophilic extract (50% CH2Cl2:CH3OH) of the orange-top 
sponge with yellow interior (PSC01-53-6) 
 
 
1H NMR spectrum (400 MHz, CDCl3) of the lipophilic extract (50% CH2Cl2:CH3OH) of the calcaneus 
bryozoan (PSC03-133-6) 
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1H NMR spectrum (400 MHz, CD3OD) of the aqueous extract (50% CH3OH:H2O) of the calcaneus 
bryozoan (PSC03-133-7) 
 
1H NMR spectrum (400 MHz, CDCl3) of the lipophilic extract (50% CH2Cl2:CH3OH) of Isodictya 
setifera (LMGSC10-108-6) 
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1H NMR spectrum (400 MHz, CD3OD) of the malaria hit (LMGSC10-108-6-7) 
 
 
1H NMR spectrum (400 MHz, CD3OD) of LMGSC10-108-6-7-4b 
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1H NMR spectrum (400 MHz, DMSO-d6) of LMGSC10-108-6-7-4b-11 
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Appendix C: Chromatograms 
 
NP MPLC chromatogram (100% hexane to 100% EtOAc) of the lipophilic extract (50% 
CH2Cl2:CH3OH) of Didemnum sp. (LMGSC10-96-6)  
 
 
 
 
NP MPLC chromatogram (100% hexane to 100% EtOAc) of the lipophilic extract (50% 
CH2Cl2:CH3OH) of dock finger sponge (PSC08-01-6) 
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NP MPLC chromatogram (100% hexane to 100% EtOAc) of the lipophilic extract (50% 
CH2Cl2:CH3OH) of Isodictya setifera (LMGSC10-108-6) 
 
 
 
 
 
 
 
 
 
 
 
25 
 
 
 
 
RP MPLC chromatograms (100% H2O to 100% CH3CN) of the malaria hit, LMGSC10-108-6-7. 
Top: insoluble portion, Bottom: 50% CH3CN:CH3OH extract 
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RP HPLC chromatogram (10% CH3CN:H2O to 100% CH3CN) of LMGSC10-108-6-7-4b 
 
 
 
LC-MS chromatogram of pure CH3OH 
 
 
 
LC-MS chromatogram (10% CH3CN:H2O to 100% CH3CN) of LMGSC10-108-6-7-4b-11 
  
Datafile Name:MSL28.lcd
Sample Name:MSL28
Sample ID:MSL28
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Appendix D: Bioassay Data 
 
 10.0 
μg/mL 
3.33 
μg/mL 
1.11 
μg/mL 
0.370 
μg/mL 
0.123 
μg/mL 
0.0412 
μg/mL 
PSC01-53-6-1a 277 507 846 893 983 995 
PSC01-53-6-5a 227 514 780 1095 1067 1221 
PSC01-53-6-2b 237 444 694 729 736 815 
PSC01-53-6-6b 179 459 698 779 827 782 
PSC03-133-6-6 179 412 586 633 705 741 
PSC03-133-6-7 209 482 655 812 937 875 
PSC03-133-6-9 158 504 710 823 930 911 
PSC03-133-6-10 285 489 757 868 932 891 
LMGSC10-96-6-3 138 405 530 651 751 713 
LMGSC10-96-6-6 200 389 588 672 884 911 
LMGSC10-108-6-7 32 94 247 397 458 411 
LMGSC10-108-6-9 35 295 556 430 473 457 
Malaria (Plasmodium falciparum 3D7) bioassay data for primary and secondary interests. Italics 
indicate 50-90% growth inhibition; bold face indicates >90% growth inhibition. 
 
 100 
μg/mL 
33.3 
μg/mL 
11.1 
μg/mL 
3.70 
μg/mL 
1.23 
μg/mL 
0.412 
μg/mL 
PSC01-53-6-1a 0.27 1.5264 1.3454 1.3012 1.1822 1.2957 
PSC01-53-6-5a 0.1986 1.5998 1.2991 1.3605 1.1974 1.2794 
PSC01-53-6-2b 0.1897 1.5075 1.3882 1.2764 1.2503 1.2001 
PSC01-53-6-6b 0.2044 1.6218 1.39 1.2767 1.2269 1.1347 
PSC03-133-6-6 0.1835 1.1254 1.481 1.3479 1.2526 1.2261 
PSC03-133-6-7 0.2333 1.842 1.3909 1.3228 1.2733 1.1678 
PSC03-133-6-9 0.1769 1.6404 1.3038 1.3072 1.199 1.1874 
PSC03-133-6-10 0.1733 1.6332 1.3158 1.3544 1.1983 1.1662 
LMGSC10-96-6-3 0.2003 1.6954 1.4447 1.3872 1.2576 1.1844 
LMGSC10-96-6-6 0.2257 1.9055 1.3974 1.3815 1.2134 1.1968 
LMGSC10-108-6-7 0.1816 1.7287 1.4501 1.3572 1.3107 1.2751 
LMGSC10-108-6-9 0.2162 1.6364 1.3816 1.2495 1.2947 1.2533 
Cytotoxicity (A549 cell line) bioassay data for primary and secondary interests. Italics indicate 
50-90% growth inhibition; bold face indicates >90% growth inhibition. 
 
 
